If you grew up in the middle of the early AIDS epidemic as I did, something I've written about firsthand, the results of a study on a tw
Gilead
The case in question concerned Gilead’s drug Tenofovir, widely prescribed for the treatment of HIV and Hepatitis B.
“Whether a duty exists is a question of law to be resolved by the court.”
On Wednesday April 29th the Dow Jones Industrial Average rose 532 points on news that Gilead's remdesivir demonstrated a “clear-cut positive effect" in treating COVID.
Pricing a new drug is not an easy task, Gilead who is producing remdesivir is no stranger to pricing controversy, the release of Solvaldi, their drug to cure Hepatitis C, had a list price of $84,000 for a full treatment course.
Six weeks of endless speculation, guessing, second-guessing, ups, and downs about whether the world would have its first effective coronavirus drug has been exhausting. I see the damn molecule in my sleep.
If there is a single company that tops the "no good deed goes unpunished" contest I would pick Gilead Sciences. By a mile.
Having spent a decade (of pure futility) in hepatitis C (HCV) research in my former career, I have spent a fair amount of time since then writing about the astounding progress made over a 25-year period.